Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027558 | 0.81 | MAPT (0.36) | ALDH1A1MAPTMAPK14LCKKIT | |
| SCHEMBL13678790 | 0.81 | RPS6KA3 (0.37) | CYP3A4CYP1A2CYP2C19GFERNPC1 | |
| SCHEMBL8150237 | 0.78 | ALKBH5 (0.43) | CYP3A4CYP1A2CYP2C19NPC1ALDH1A1 | |
| SCHEMBL3568818 | 0.77 | DGAT1 (0.43) | RAB9ASMN1; SMN2MAPK14KCNH2 | |
| SCHEMBL8266914 | 0.76 | F2 (0.42) | CYP3A4CYP1A2NPC1ALDH1A1MAPT | |
| SCHEMBL92865 | 0.76 | NPC1 (0.54) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8306336 | 0.74 | MAPK14 (0.43) | MAPTMAPK14KCNH2AOC3CYP2A6 | |
| SCHEMBL15889916 | 0.72 | CYP19A1 (0.51) | CYP3A4CYP1A2CYP2C19MAPTCYP19A1 | |
| SCHEMBL8337902 | 0.72 | CYP2A6 (0.49) | CYP3A4ALDH1A1MAPK14KCNH2CYP19A1 | |
| SCHEMBL14490257 | 0.71 | CYP2A6 (0.43) | CYP3A4ALDH1A1MAPTMAPK14CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006048152-A2 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004031145-A2 | LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | F2, F12, TFPI | CYP3A4 182/4885CYP1A2 299/4885CYP2C19 113/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | CYP3A4 1311/4885CYP1A2 2478/4885CYP2C19 1307/4885 |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | CYP3A4 2461/4885CYP1A2 2248/4885CYP2C19 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.